Cozad Asset Management Inc. Invests $556,000 in United Therapeutics Corporation (NASDAQ:UTHR)

Cozad Asset Management Inc. acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 1,805 shares of the biotechnology company's stock, valued at approximately $556,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dunhill Financial LLC boosted its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in shares of United Therapeutics during the 1st quarter worth $49,000. State of Wyoming purchased a new stake in shares of United Therapeutics during the 4th quarter worth $62,000. Curat Global LLC purchased a new stake in shares of United Therapeutics during the 1st quarter worth $63,000. Finally, Natixis purchased a new stake in shares of United Therapeutics during the 4th quarter worth $85,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

UTHR stock traded up $19.58 during trading on Friday, hitting $294.28. The stock had a trading volume of 2,428,905 shares, compared to its average volume of 426,182. The company's 50 day moving average price is $298.13 and its two-hundred day moving average price is $313.59. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The stock has a market cap of $13.27 billion, a price-to-earnings ratio of 11.49, a price-to-earnings-growth ratio of 5.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period in the previous year, the firm posted $5.85 EPS. The company's revenue for the quarter was up 11.7% compared to the same quarter last year. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer owned 8,118 shares of the company's stock, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director directly owned 4,883 shares of the company's stock, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 70,681 shares of company stock worth $21,318,359. 10.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on UTHR shares. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Wells Fargo & Company cut their price target on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a research note on Thursday. HC Wainwright set a $400.00 price target on United Therapeutics and gave the stock a "buy" rating in a research note on Thursday. UBS Group cut their price target on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday, June 30th. Finally, Bank of America cut their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $379.69.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.